Search Results

Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024.

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region.

The Department of Health – Abu Dhabi, the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding with Roche Pharmaceuticals Middle East during Abu Dhabi Global Healthcare Week.

Aurinia Pharmaceuticals Inc., announced the presentation of two studies at the annual Congress of Clinical Rheumatology East 2024 taking place in Destin, FL, May 9-12.

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that Caroline Loew, Ph.D., CEO, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST.

CMR Surgical, the global surgical robotics business, announces that Sushobhan Dasgupta has joined the Company as President and Chief Commercial Officer for Asia Pacific, the Middle East and Africa.

Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq.

QIAGEN announced a significant expansion of its business in the Middle East region, which includes three major developments.